Treatment with therapeutic anticoagulation is not associated with immunotherapy response in advanced cancer patients
Abstract Background Recent preclinical data suggest that there may be therapeutic synergy between immune checkpoint blockade and inhibition of the coagulation cascade. Here, we investigate whether patients who received immune checkpoint inhibitors (ICI) and were on concomitant anticoagulation (AC) e...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2021-01-01
|
| Series: | Journal of Translational Medicine |
| Online Access: | https://doi.org/10.1186/s12967-021-02712-w |
| _version_ | 1818877746318671872 |
|---|---|
| author | Paul Johannet Amelia Sawyers Nicholas Gulati Douglas Donnelly Samuel Kozloff Yingzhi Qian Alfredo Floristan Eva Hernando Judy Zhong Iman Osman |
| author_facet | Paul Johannet Amelia Sawyers Nicholas Gulati Douglas Donnelly Samuel Kozloff Yingzhi Qian Alfredo Floristan Eva Hernando Judy Zhong Iman Osman |
| author_sort | Paul Johannet |
| collection | DOAJ |
| description | Abstract Background Recent preclinical data suggest that there may be therapeutic synergy between immune checkpoint blockade and inhibition of the coagulation cascade. Here, we investigate whether patients who received immune checkpoint inhibitors (ICI) and were on concomitant anticoagulation (AC) experienced better treatment outcomes than individuals not on AC.Affiliation: Kindly confirm if corresponding authors affiliation is identified correctly.The corresponding author's affiliation is correct. Methods We studied a cohort of 728 advanced cancer patients who received 948 lines of ICI at NYU (2010–2020). Patients were classified based on whether they did (n = 120) or did not (n = 828) receive therapeutic AC at any point during their treatment with ICI. We investigated the relationship between AC status and multiple clinical endpoints including best overall response (BOR), objective response rate (ORR), disease control rate (DCR), progression free survival (PFS), overall survival (OS), and the incidence of bleeding complications.Affiliations: Journal instruction requires a country for affiliations; however, this is missing in affiliations 1 to 5. Please verify if the provided country is correct and amend if necessary.The country is correct for all affiliations (1 - 5). Results Treatment with AC was not associated with significantly different BOR (P = 0.80), ORR (P =0.60), DCR (P =0.77), PFS (P = 0.59), or OS (P =0.64). Patients who received AC were significantly more likely to suffer a major or clinically relevant minor bleed (P = 0.05). Conclusion AC does not appear to impact the activity or efficacy of ICI in advanced cancer patients. On the basis of our findings, we caution that there is insufficient evidence to support prospectively evaluating the combination of AC and immunotherapy. |
| first_indexed | 2024-12-19T14:03:11Z |
| format | Article |
| id | doaj.art-15ede8d1e7544f3dbfb66cf0ce0798ad |
| institution | Directory Open Access Journal |
| issn | 1479-5876 |
| language | English |
| last_indexed | 2024-12-19T14:03:11Z |
| publishDate | 2021-01-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Translational Medicine |
| spelling | doaj.art-15ede8d1e7544f3dbfb66cf0ce0798ad2022-12-21T20:18:23ZengBMCJournal of Translational Medicine1479-58762021-01-011911710.1186/s12967-021-02712-wTreatment with therapeutic anticoagulation is not associated with immunotherapy response in advanced cancer patientsPaul Johannet0Amelia Sawyers1Nicholas Gulati2Douglas Donnelly3Samuel Kozloff4Yingzhi Qian5Alfredo Floristan6Eva Hernando7Judy Zhong8Iman Osman9Department of Medicine, NYU Langone HealthRonald O. Perelman Department of Dermatology, NYU Langone HealthRonald O. Perelman Department of Dermatology, NYU Langone HealthRonald O. Perelman Department of Dermatology, NYU Langone HealthDepartment of Medicine, NYU Langone HealthDepartment of Population Health, NYU Langone HealthDepartment of Pathology, NYU Langone HealthDepartment of Pathology, NYU Langone HealthDepartment of Population Health, NYU Langone HealthRonald O. Perelman Department of Dermatology, NYU Langone HealthAbstract Background Recent preclinical data suggest that there may be therapeutic synergy between immune checkpoint blockade and inhibition of the coagulation cascade. Here, we investigate whether patients who received immune checkpoint inhibitors (ICI) and were on concomitant anticoagulation (AC) experienced better treatment outcomes than individuals not on AC.Affiliation: Kindly confirm if corresponding authors affiliation is identified correctly.The corresponding author's affiliation is correct. Methods We studied a cohort of 728 advanced cancer patients who received 948 lines of ICI at NYU (2010–2020). Patients were classified based on whether they did (n = 120) or did not (n = 828) receive therapeutic AC at any point during their treatment with ICI. We investigated the relationship between AC status and multiple clinical endpoints including best overall response (BOR), objective response rate (ORR), disease control rate (DCR), progression free survival (PFS), overall survival (OS), and the incidence of bleeding complications.Affiliations: Journal instruction requires a country for affiliations; however, this is missing in affiliations 1 to 5. Please verify if the provided country is correct and amend if necessary.The country is correct for all affiliations (1 - 5). Results Treatment with AC was not associated with significantly different BOR (P = 0.80), ORR (P =0.60), DCR (P =0.77), PFS (P = 0.59), or OS (P =0.64). Patients who received AC were significantly more likely to suffer a major or clinically relevant minor bleed (P = 0.05). Conclusion AC does not appear to impact the activity or efficacy of ICI in advanced cancer patients. On the basis of our findings, we caution that there is insufficient evidence to support prospectively evaluating the combination of AC and immunotherapy.https://doi.org/10.1186/s12967-021-02712-w |
| spellingShingle | Paul Johannet Amelia Sawyers Nicholas Gulati Douglas Donnelly Samuel Kozloff Yingzhi Qian Alfredo Floristan Eva Hernando Judy Zhong Iman Osman Treatment with therapeutic anticoagulation is not associated with immunotherapy response in advanced cancer patients Journal of Translational Medicine |
| title | Treatment with therapeutic anticoagulation is not associated with immunotherapy response in advanced cancer patients |
| title_full | Treatment with therapeutic anticoagulation is not associated with immunotherapy response in advanced cancer patients |
| title_fullStr | Treatment with therapeutic anticoagulation is not associated with immunotherapy response in advanced cancer patients |
| title_full_unstemmed | Treatment with therapeutic anticoagulation is not associated with immunotherapy response in advanced cancer patients |
| title_short | Treatment with therapeutic anticoagulation is not associated with immunotherapy response in advanced cancer patients |
| title_sort | treatment with therapeutic anticoagulation is not associated with immunotherapy response in advanced cancer patients |
| url | https://doi.org/10.1186/s12967-021-02712-w |
| work_keys_str_mv | AT pauljohannet treatmentwiththerapeuticanticoagulationisnotassociatedwithimmunotherapyresponseinadvancedcancerpatients AT ameliasawyers treatmentwiththerapeuticanticoagulationisnotassociatedwithimmunotherapyresponseinadvancedcancerpatients AT nicholasgulati treatmentwiththerapeuticanticoagulationisnotassociatedwithimmunotherapyresponseinadvancedcancerpatients AT douglasdonnelly treatmentwiththerapeuticanticoagulationisnotassociatedwithimmunotherapyresponseinadvancedcancerpatients AT samuelkozloff treatmentwiththerapeuticanticoagulationisnotassociatedwithimmunotherapyresponseinadvancedcancerpatients AT yingzhiqian treatmentwiththerapeuticanticoagulationisnotassociatedwithimmunotherapyresponseinadvancedcancerpatients AT alfredofloristan treatmentwiththerapeuticanticoagulationisnotassociatedwithimmunotherapyresponseinadvancedcancerpatients AT evahernando treatmentwiththerapeuticanticoagulationisnotassociatedwithimmunotherapyresponseinadvancedcancerpatients AT judyzhong treatmentwiththerapeuticanticoagulationisnotassociatedwithimmunotherapyresponseinadvancedcancerpatients AT imanosman treatmentwiththerapeuticanticoagulationisnotassociatedwithimmunotherapyresponseinadvancedcancerpatients |